1700001C02Rik Inhibitors
Chemical inhibitors of 1700001C02Rik operate through diverse mechanisms to reduce the activity of this protein within cellular signaling pathways. Triciribine acts by targeting Akt, a kinase that functions downstream of various growth factors and upstream of 1700001C02Rik. By impeding Akt's activity, triciribine indirectly prevents the phosphorylation and subsequent activation of 1700001C02Rik. Similarly, LY294002 and Wortmannin exert their effects through the inhibition of PI3K, an upstream regulator of Akt. These inhibitors collectively lead to a decrease in Akt-mediated signaling, thereby limiting the phosphorylation and the functional state of 1700001C02Rik. Rapamycin, on the other hand, forms a complex with FKBP12 and selectively inhibits mTORC1, which is intricately connected to cellular growth and metabolism. By disrupting mTORC1 signaling, rapamycin suppresses several downstream processes, potentially including the translation or activity of 1700001C02Rik.
In a parallel approach, PD98059 and U0126 target MEK1/2 within the MAPK/ERK pathway, a pivotal route for cellular division and differentiation signals. The inhibition of MEK by these chemicals prevents the activation of ERK, which in turn may halt the phosphorylation of 1700001C02Rik, resulting in its functional inhibition. Furthermore, SP600125 interferes with the JNK signaling pathway by inhibiting JNK itself, which could be essential for 1700001C02Rik's activity. SB203580 disrupts the p38 MAP kinase pathway, another axis of the response to stress and inflammation, potentially attenuating the activation of downstream proteins such as 1700001C02Rik. PP2 targets Src family tyrosine kinases, which are pivotal for several cellular proliferation and survival pathways. By inhibiting Src kinases, PP2 may disrupt pathways that lead to the functional activation of 1700001C02Rik. In the realm of tyrosine kinase receptor inhibition, Gefitinib and Erlotinib specifically inhibit EGFR, which is known to be a starting point for a multitude of signaling cascades. The action of these inhibitors leads to a reduction in the activation of downstream pathways that are responsible for the functional state of 1700001C02Rik. Each of these chemicals, by interfering with specific kinases or signaling molecules, contributes to the collective downregulation of 1700001C02Rik activity within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits Akt, a kinase downstream of many growth factor receptors and upstream of 1700001C02Rik. Inhibition of Akt by Triciribine would lead to reduced phosphorylation and activation of downstream targets, including 1700001C02Rik, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and specifically inhibits mTORC1, a central regulator of cell growth and metabolism that can regulate protein translation and transcription. Since mTORC1 has downstream effects on protein synthesis, its inhibition by Rapamycin may result in functional inhibition of 1700001C02Rik by limiting its availability or activity within the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK, which is part of the MAPK/ERK pathway. As MEK is upstream of ERK, its inhibition would prevent ERK from phosphorylating downstream targets, potentially including 1700001C02Rik. This would result in the functional inhibition of 1700001C02Rik as a consequence of blocked activation signaling through the MAPK/ERK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which can influence various downstream signaling pathways including Akt. By inhibiting PI3K, LY294002 can decrease the activation of Akt and subsequent downstream targets that might include 1700001C02Rik, leading to the functional inhibition of the protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in stress-activated protein kinase signaling pathways. Inhibition of JNK by SP600125 would prevent the phosphorylation of substrates within the JNK pathway, which may be necessary for the activity of 1700001C02Rik, thereby inhibiting 1700001C02Rik function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. p38 MAP kinase is a key player in inflammatory and stress responses, and its inhibition can affect downstream signaling. By inhibiting p38 MAPK, SB203580 could prevent the phosphorylation and activation of downstream proteins, including 1700001C02Rik, thus functionally inhibiting 1700001C02Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 specifically inhibits MEK1/2, enzymes in the MAPK/ERK pathway. This pathway is crucial for the regulation of cell division, differentiation, and secretion. By inhibiting MEK1/2, U0126 would block the activation of ERK and the subsequent phosphorylation of downstream targets, potentially including 1700001C02Rik, leading to the functional inhibition of 1700001C02Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific and potent inhibitor of PI3K. The PI3K pathway plays a significant role in cell survival and growth, and by inhibiting PI3K, Wortmannin can decrease the activity of downstream targets, such as Akt, and subsequently 1700001C02Rik, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases are involved in various signaling pathways related to cell proliferation and survival. By inhibiting Src kinases, PP2 could disrupt signaling pathways that lead to the functional activation of 1700001C02Rik, resulting in its functional inhibition. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the activation of several downstream signaling pathways, including those that lead to the activation of 1700001C02Rik. By inhibiting EGFR, Gefitinib would lead to reduced activation of these downstream pathways, resulting in the functional inhibition of 1700001C02Rik. | ||||||